JOHNSON & JOHNSON — Director's Dealing 2025

Jul 18, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: JOHNSON & JOHNSON (JNJ)
CIK: 0000200406
Period of Report: 2025-07-17

Reporting Person: REED JOHN C (EVP, Innovative Medicine, R&D)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-07-17	Common Stock	S	19137	$163.5486	Disposed	10658	Direct

Footnotes

F1: This transaction was executed in multiple trades at prices ranging from $163.52 to $163.61. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.